RxDoctor Payments Data

Reed Holland, DO

Internal Medicine · Bradenton, FLNPI 1083929194

Payments from drug & device makers

$324in general payments, 2019–2025

Across 18 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$72
  • Laborie Medical Technologies Corp.$30
  • Boston Scientific$27
  • Novartis$26
  • Kowa Pharmaceuticals America, Inc.$24
  • Abbott$22
  • plus $124 from 8 others

What the payments were for

  • Food & beverage$324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$324 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$308,582
Medicare patients
845
Services billed
3,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$121,167
EliquisApixaban69$104,206
XareltoRivaroxaban47$62,659
JardianceEmpagliflozin36$55,116
JanuviaSitagliptin Phosphate21$33,659
TrulicityDulaglutide33$33,485
MounjaroTirzepatide23$32,024
FarxigaDapagliflozin Propanediol17$27,445
EntrestoSacubitril/Valsartan12$21,057
InvokanaCanagliflozin17$15,370
MyrbetriqMirabegron16$11,494
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,860
Tresiba Flextouch U-100Insulin Degludec11$6,489
Atorvastatin Calcium652$6,488
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$5,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$72$78,02964 claims
Lilly USA, LLCTrulicity, Mounjaro$13$65,50956 claims
MerckJanuvia$13$33,65921 claims
AstraZenecaFarxiga$11$27,44517 claims
NovartisEntresto$26$21,05712 claims
Astellas Pharma US IncMyrbetriq$22$11,49416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →